



OSTEOSTRAND® PLUS


100% DEMINERALIZED BONE FIBERS WITH ACCELL® BONE MATRIX

BACKED BY SCIENCE

OsteoStrand® Plus fibers were developed through a disciplined R&D process that evaluated a variety of fiber geometries to deliver osteoinductivity, osteoconductivity, intraoperative handling and controlled expansion. OsteoStrand Plus is 100% demineralized bone fibers designed to unleash the maximum bone forming capacity and fusion potential. Combined with Accell Bone Matrix (ABM), OsteoStrand Plus provides both immediate and sustained release of growth factors critical to bone healing.


Cellular Highways: Fiber Geometry Maximizes Osteoconductivity

Martin et al., 19991



Study Conclusions

- Devitalized fibers (growth factors eliminated) generate 35% fusion
- Fiber geometry maximizes osteoconductivity compared to particle geometry



Early Bone Fusion Achieved with OsteoStrand Family Fibers

Olsson et al., 2023²









Example of two-level ACDF X-ray preoperation through 12 months postoperation

OSTEOSTRAND® PLUS FEATURES


Specific Geometry

Long fibers provide exceptional handling and controlled expansion.



The Accell® Advantage

Patented ABM provides earlier access to naturally occurring bone proteins.





In Vitro Measure of BMP-2 Over Time



Time

Expands to Fill Gaps

Wicks blood, bone marrow, and other physioloimprove fill.



Fluid expressed



Moldable and Cohesive

Entangled fibers create a 3D interconnected matrix, removing the need for a carrier.



Simplicity of Hydration

Dried fibers extend shelf life while preserving osteoinductive potential. Luer lock portal (syringe option only) delivers a simple yet thorough hydration process with various hydration fluids.




Procedural Integration

Compatible with RAPID® System for seamless graft delivery.

DBM Quality and Quantity Matter


Russell et al., 2020³, He, et al., 2022⁴

Fusion by µCT Bridging



*Indicates statistical significance relative to OsteoStrand family

Russell et al., 2020³



4-week μCT of OsteoStrand $^{\circ}$ family

Study Conclusions

- OsteoStrand family fibers achieved 100% fusion
- DBM composition does not guarantee performance
- Strict tissue processing and quality standards correspond with improved product performance

OSTEOSTRAND® PLI

100% DEMINERALIZED BONE FIBERS WITH ACCELL® BONE MATRIX

OSTEOSTRAND® PLUS ORDERING INFORMATION





Syringe

Product Volume	Part Number
X-small (1.25cc)	56730010
Small (2.5cc)	56730025
Medium (5cc)	56730050
Large (10cc)	56730100

Vial

Product Volume	Part Number
X-small (1.25cc)	56710010
Small (2.5cc)	56710025
Medium (5cc)	56710050
Large (10cc)	56710100

Refer to instructions for use for indications and important safety instructions.

For more information or to place an order, please contact: TEL 866.942.8698 | FAX 877.558.6227 customerservice@seaspine.com | seaspine.com

Outside USA

TEL +1.760.727.8399 | FAX +1.760.727.8809 INTERNATIONAL INQUIRIES intlcustomer@seaspine.com

■ IsoTis OrthoBiologics, Inc.

2 Goodvear, Irvine CA 92618 TEL 800.550.7155 | FAX 800.471.3248 web seaspine.com

IsoTis OrthoBiologics, Inc. is a member of the SeaSpine Orthopedics Corporation family of companies. Made in the USA





Warning: Applicable laws restrict these products to sale by or on the order of a physician. SeaSpine, Orthofix, their respective logos, Accell, OsteoStrand, and RAPID are trademarks or registered trademarks of Orthofix Medical Inc. and/or its affiliate companies. All other trademarks, services marks or trade names are the property of their respective owners. Use or display by us of other parties' trademarks, service marks, trade names, trade dress or products is not intended to and does not imply a relationship with, or endorsements or sponsorship of, use by the trademark, service mark, trade name, trade dress or product owners. © SeaSpine Orthopedics Corporation. 12/2023. All rights reserved. D0006436B101

¹Martin Jr, G. J., Boden, S. D., Titus, L., & Scarborough, N. L. (1999). New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. Spine, 24(7), 637-645.

²⁰Isson, E. (2023). The Achievement of Early Bony Fusion after Use of the OsteoStrand® Family Fibers in Single and Multi-Level Anterior Discectomy and Fusion: A Case Series. SeaSpine White Paper

³Russell, N., Walsh, W. R., Lovric, V., Kim, P., Chen, J. H., Larson, M. J., & Vizesi, F. (2020). In-vivo performance of seven commercially available demineralized bone matrix fiber and putty products in a rat posterolateral fusion model. Frontiers in Surgery, 7, 10.

⁴He, J., Larsen, M., Oliver, R., Lovric, V., Walsh, W. & Vizesi, F. (2022). Comparison of Commercially Available Orthobiologics in a Rat Spinal Fusion Model: OsteoAMP Select Flowable. SeaSpine White Paper